MARIPOSA-2: Is the treatment worse than the disease?

Alexandria T M Lee; Sai-Hong Ignatius Ou

doi:10.1016/j.medj.2023.12.010

MARIPOSA-2: Is the treatment worse than the disease?

Med. 2024 Feb 9;5(2):115-117. doi: 10.1016/j.medj.2023.12.010.

Authors

Alexandria T M Lee¹, Sai-Hong Ignatius Ou²

Affiliations

¹ University of California Irvine School of Medicine, Department of Medicine, Orange, CA 92868, USA.
² University of California Irvine School of Medicine, Department of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA. Electronic address: ignatiusou@gmail.com.

PMID: 38340706
DOI: 10.1016/j.medj.2023.12.010

Abstract

Passaro et al.¹ demonstrated in EGFR+ NSCLC post-1L osimertinib both "quad" (lazertinib [L] + amivantamab [A] + chemotherapy [CP]) and "triplet" (ACP) regimens achieved improved median progression-free survival over CP. Nonetheless, a high incidence of adverse events requiring dose modifications may limit adaptation of the triplet and quad MARIPOSA-2 regimens.

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
ErbB Receptors / genetics
ErbB Receptors / therapeutic use
Humans
Lung Neoplasms* / drug therapy
Mutation

Substances

ErbB Receptors